

REMARKS

The Specification and Claims have been amended to include SEQ ID numbers which were omitted at the time of filing.

The undersigned hereby states that the computer readable form copy (CFR copy) of the Sequence Listing and the paper copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this sequence listing and the U.S. Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this sequence listing to our Deposit Account No. 03-1952. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: August³¹, 2001

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

EXHIBIT A. - VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Page 3, line 28,

Figures 3A - 3D show[s] the complete nucleotide sequence (SEQ ID NO:1) and deduced amino acid sequence (SEQ ID NO:2) of a single chain TCR derivative which contains variable α and β specific for HA linked through a short peptide linker and then fused through a CD8 hinge to the ζ chain.

Page 4, line 8,

Figures 6A - 6B show[s] the sequence of various primers (SEQ ID NOS:3-42) useful in cloning or amplifying the nucleotide sequences in coding during variable regions of α and β TCR chains.

Page 4, line 10,

Figures 7A - 7D show the nucleotide sequence (SEQ ID NOS:43 and 45) and deduced amino acid sequence (SEQ ID NOS:44 and 46) of the variable regions of the α and β chains of H7-specific TCR respectively.

Page 9, line 1,

Tabl 1. Her-2/neu peptides used f r immunizati n				
PEPTIDE	SEQUENC E #	SEQUENCE	IMMUNOGENICIT Y	% INHIBITION
H3 (SEQ ID NO:47)	369-377	KIFGSLAFL	+	38
H6 (SEQ ID NO:48)	444-453	TLQGLGISWL	-	56
H7 (SEQ ID NO:49)	773-782	VMAGVGSPYV	+	55
H8 (SEQ ID NO:50)	546-555	VLQGLPREYV	-	43
H12 (SEQ ID NO:51)	48-56	HLYQGOQW	-	15
H13 (SEQ ID NO:52)	689-697	RLLQETELV	-	56
H14 (SEQ ID NO:53)	747-755	KIPVAIKVL	-	35
H15 (SEQ ID NO:54)	789-797	CLTSTVQLV	-	33
H16 (SEQ ID NO:55)	799-807	QLMPYGCLL	-	50
H17 (SEQ ID NO:56)	851-859	VLVKSPNHV	-	12
H18 (SEQ ID NO:57)	871-879	DIDETEHYA	-	37
H19 (SEQ ID NO:58)	933-941	DLLEKGERL	-	36
H20 (SEQ ID NO:59)	971-979	ELVSEFSRM	-	5
H21 (SEQ ID NO:60)	971-980	ELVSEFSRMA	-	25
H22 (SEQ ID NO:61)	972-980	LVSEFSRMA	-	14
H23 (SEQ ID NO:62)	1016-1024	DLVDAEEYL	-	35
H24 (SEQ ID NO:63)	1172-1180	TLSPGKNGV	-	57
HIV-9K (SEQ ID NO:64)	POL	KLVGKLNWA	+	80

In the Claims:

5. (Amended) The nucleic acid molecule of claim 11 wherein said flexible linker is of the formula $(\text{Gly}_4\text{Ser}_3)_3$ (SEQ ID NO:65).